Akero Therapeutics Inc Net Income per Employee (AKRO), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
Akero Therapeutics Inc   (NASDAQ: AKRO)
 

Akero Therapeutics Inc Net Income per Employee

AKRO's Quarterly Results, Trends, Rankings, Statistics
Akero Therapeutics Inc recorded a cumulative net loss of $-293 million during 12 month ending in the third quarter 2025.
The Healthcare sector has seen employees of 418 other companies achieving higher income per employee. While Akero Therapeutics Inc 's total ranking has deteriorated compared to the previous quarter from 2712 to 4111.


What is Income per Employee Ratio?





Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

AKRO Net Income per Employee (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter		 (Dec 31 2024)
IV. Quarter		 (Sep 30 2024)
III. Quarter
Y / Y Net Income Change - - - - -
Net Income per Employee (TTM) $ -5,228,929 -5,070,696 -4,811,446 -4,501,071 -4,236,107
AKRO's Total Ranking # 4111 # 2712 # 2932 # 2204 # 2237
Seq. Net Income Change - - - - -

AKRO Company Profile >> Back to AKRO Efficiency Comparisons >> Compare AKRO Net Income per Employee to its Competitors

AKRO Net Income per Employee Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 419
Healthcare Sector # 877
Overall Market # 4111

Net Income per Employee Statistics
High Average Low
$ -277,750 $ -2,489,293 $ -5,228,929
(Sep 30 2019)   (Sep 30 2025)




  News about Akero Therapeutics Inc Income per employee

Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares, Marking a Significant Milestone in Advancing Revolutionary Treatments for Metabolic Diseases.

Akero Therapeutics, Inc. has recently announced the successful closing of its underwritten public offering of common stock, along with the full exercise of underwritersn option to purchase additional shares. This clinical-stage company focuses on developing innovative treatments for patients suffering from serious metabolic diseases, characterized by a high unmet medical need.
The public offering involved the issuance of 12,650,000 shares of common stock at a price of $29.00 per share, which includes the underwriters decision to exercise their option to purchase an additional 1,650,000 shares. The total gross proceeds from this offering, before deducting underwriting discounts and commissions as well as estimated expenses, reached approximately $366.9 million.




Companies with similar Income per Employee for 12 month ending Sep 30 2025, within Healthcare Sector Income per Employee Income 12 month ending Sep 30 2025Number of Employees Sep 30 2025


Date modified: 2026-09-08T15:11:34+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.